Fact 3: The Classification
NHL isn’t a one-size-fits-all diagnosis. It’s a spectrum with multiple subtypes, primarily divided into two categories: B-cell lymphomas and T-cell lymphomas. Let’s delve deeper.
B-cell lymphomas are more common, making up about 85% of NHL cases in the U.S. The B-cells, integral to our immunity, produce antibodies to counter threats. When these cells become malignant, different subtypes of NHL can manifest, such as diffuse large B-cell lymphoma or follicular lymphoma.
T-cell lymphomas are rarer. T-cells are the body’s defenders, playing a central role in identifying and eliminating harmful invaders. These lymphomas can affect the skin, leading to conditions like mycosis fungoides, or impact other parts of the body.
Understanding the classification isn’t just academic. It’s pivotal for treatment. Each subtype requires a specific treatment approach. The nature of the disease, its progression rate, and its impact on the patient’s health vary based on its classification. (3)
